Company Profile
Nucleus Network
Company Overview
Phase One, Two Countries, Three Clinics
Nucleus Network is Australia’s largest Phase 1 clinical research organization and the only Phase 1 specialist globally with facilities in the USA and Australia. Since our establishment in 2004, Nucleus Network has conducted well over 1000 Phase 1 clinical trials for Biotechnology and Pharmaceutical Companies from across the globe, including China, Europe, Japan, South Korea, Taiwan and the USA.
Our Australian Phase 1 facilities are in Melbourne and Brisbane, and our USA Phase 1 facility is in Minneapolis. Combined, our clinics offer over 200 beds. All three clinics are strategically co-located within leading medical, research and biotech precincts; the Alfred Hospital in Melbourne, the Royal Brisbane and Women’s Hospital in Brisbane, and Medical Alley in Minnesota.
These precincts provide Nucleus Network with unique access to highly specialized ancillary services for the conduct of complex Phase 1 clinical trials. From specialist PD equipment for first in human studies in Melbourne, purpose-built infrastructure for high volume biosimilar studies in Brisbane, and onsite dialysis capabilities for complicated renal studies in Minneapolis, Nucleus Network has the experience to conduct the most complex early phase clinical trials.
Together with our clients, we are fulfilling our purpose of "Advancing medicine, improving lives."
Company History
Nucleus Network was established with Victorian Government funding in 2003 by the Baker IDI Heart and Diabetes Institute.
Under the leadership of then-Director, Professor Gary Jennings AO, it was at the heart of a strategy to accelerate research translation and better health outcomes for patients.
Like most outstanding ideas, Nucleus Network grew quickly, forming a reputation as an early phase clinical trial specialist for conducting Phase 1 clinical trials, including complex First-in-Human healthy and patient trials for Biotechnology and Pharmaceutical companies.
With an eye on the US market, it became clear to Baker IDI that Nucleus Network had potential to scale well beyond the initial scope. In 2018, the sale of Nucleus Network to Crescent Capital Partners signaled a transformation from a single site with a niche offering, to a company that could make an impact at a global level, and service some of the industry’s largest and most respected clients in the sector.
By 2019, Nucleus Network had expanded its capabilities and access to patient trial participants with the acquisition of additional specialist facilities in Brisbane (Q-Pharm) and the USA (Prism) all brought under the Nucleus Network banner. This positions Nucleus Network as the first and only multi-site Phase 1 clinical trial organization with clinics in both Australia and the USA.
In late 2021, Nucleus Network's continued expansion in profile and capability made it an attractive acquisition for several investment groups, and on March 1st 2022 the sale was finalized and Nucleus Network was acquired by one of the world's largest private equity firms, Blackstone.
We are undergoing an exciting global transformation. With expanded capability and the capacity to offer a true one-of-a-kind flexible, multi-site specialized service, Nucleus Network is setting new standards across the sector and is helping re-imagine the future of early-stage clinical trial conduct.
Benefits
Meaningful Impact - 'advancing medicine, improving lives' of people around the world
Professional Growth Opportunities - We believe in investing in our employees' development
Employee Recognition - Your hard work and achievements will be recognised and rewarded
Employee Wellness Initiatives - We prioritize the health and wellbeing of our employee
